What it's for (Indications)
- Flupenthixol is primarily indicated for the treatment of schizophrenia and other psychoses, including acute exacerbations and chronic forms characterized by positive symptoms (e.
- g.
- , hallucinations, delusions, thought disorder) and negative symptoms (e.
- g.
- , apathy, withdrawal).
- Its therapeutic utility extends to managing severe agitation and aggression associated with these psychiatric conditions.
- The long-acting injectable (depot) formulation, flupenthixol decanoate, is particularly beneficial for maintenance therapy in chronic schizophrenia, aiming to improve treatment adherence and prevent relapse.
- At lower oral doses, flupenthixol is also utilized as an antidepressant or anxiolytic, specifically for moderate to severe anxiety and as an adjuvant in chronic depression, especially when presenting with features of apathy, asthenia, and loss of initiative, where other antidepressant treatments may have been ineffective or poorly tolerated.
- Its efficacy spans both acute symptom management and long-term stabilization in appropriate patient populations.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Flupenthixol dosage is highly individualized and must be determined by a healthcare professional based on the patient's clinical condition, response to treatment, tolerance, and the specific formulation used (oral tablets or long-acting injectable depot). For oral administration in acute psychosis, an initial dose typically ranges from 3 mg to 9 mg daily, usually divided into two or three doses. This may be gradually increased to a usual maximum of 18 mg to 20 mg daily, though some severe cases may necessitate higher doses under strict medical supervision. Maintenance oral doses generally range from 3 mg to 18 mg daily. For the long-acting injectable (depot) formulation, flupenthixol decanoate is administered intramuscularly, commonly every two to four weeks. Initial depot doses might be 20 mg to 40 mg (1 mL or 2 mL of a 20 mg/mL solution), with subsequent doses adjusted according to clinical response, often up to 200 mg every 2-4 weeks for maintenance therapy in chronic schizophrenia. For anxiety and depression, significantly lower oral doses, typically 0.5 mg to 3 mg daily, are employed. Dose adjustments are crucial in elderly patients, those with hepatic or renal impairment, and when co-administering with other central nervous system depressants, requiring careful monitoring to mitigate adverse effects. |
Safety & Warnings
Common Side Effects
- Flupenthixol, like other typical antipsychotics, can induce a wide range of side effects primarily due to its dopaminergic and other receptor-blocking activities.
- Extrapyramidal symptoms (EPS) are common and may include akathisia (restlessness), dystonia (sustained muscle contractions), parkinsonism (tremor, rigidity, bradykinesia), and potentially irreversible tardive dyskinesia (involuntary, repetitive movements, particularly of the face and tongue) with chronic use.
- Other frequently reported side effects include sedation, drowsiness, dry mouth, blurred vision, constipation, and urinary retention, attributable to its anticholinergic properties.
- Cardiovascular effects such as orthostatic hypotension, tachycardia, and QTc prolongation, which carries a risk of serious ventricular arrhythmias like Torsades de Pointes, have been documented.
- While less prominent than with some atypical antipsychotics, metabolic changes including weight gain, dyslipidemia, and hyperglycemia can occur.
- Endocrine disturbances, notably hyperprolactinemia, can lead to conditions such as amenorrhea, galactorrhea, gynecomastia, and sexual dysfunction.
- Less common but serious adverse events include neuroleptic malignant syndrome (NMS), seizures, blood dyscrasias (e.
- g.
- , leukopenia, neutropenia, agranulocytosis), and hepatic dysfunction.
- Vigilant monitoring for the emergence of any adverse reactions is essential during flupenthixol therapy.
Serious Warnings
- Black Box Warning: Elderly patients with dementia-related psychosis treated with antipsychotic drugs, including flupenthixol, are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), predominantly involving atypical antipsychotic drugs, consistently demonstrated a risk of death in drug-treated patients that was between 1.6 to 1.7 times higher than that observed in placebo-treated patients. Over the course of a typical 10-week controlled trial, the observed rate of death in drug-treated patients was approximately 4.5%, compared to an approximate rate of 2.6% in the placebo group. While the causes of death were varied across these studies, the majority of fatalities appeared to be cardiovascular in nature (e.g., heart failure, sudden death) or infectious (e.g., pneumonia). Flupenthixol is not approved by regulatory authorities for the treatment of dementia-related psychosis. Healthcare professionals should exercise extreme caution and thoroughly weigh the potential benefits against the significant risks when considering the use of flupenthixol in this vulnerable population, exploring alternative management strategies for behavioral symptoms associated with dementia.
- Flupenthixol treatment requires careful consideration due to several important warnings and potential serious adverse events.
- Neuroleptic Malignant Syndrome (NMS), a rare but life-threatening idiosyncratic reaction characterized by high fever, severe muscular rigidity, altered mental status, and autonomic instability, necessitates immediate discontinuation of flupenthixol and intensive symptomatic treatment.
- Tardive dyskinesia, a syndrome of potentially irreversible, involuntary dyskinetic movements, particularly of the face and extremities, can develop during chronic therapy or after discontinuation; regular assessment for abnormal movements is crucial.
- QTc interval prolongation and an increased risk of serious ventricular arrhythmias, including Torsades de Pointes, are significant concerns, especially in patients with pre-existing cardiac conditions, electrolyte imbalances, or concomitant use of other QTc-prolonging medications; ECG monitoring should be considered.
- Patients with a history of seizures or conditions that lower the seizure threshold should be treated with caution, as flupenthixol can exacerbate these conditions.
- Orthostatic hypotension, leading to dizziness and falls, particularly during initial dosing or dose escalation, poses a risk, especially in elderly or debilitated patients.
- Metabolic changes, including hyperglycemia, dyslipidemia, and weight gain, should be routinely monitored.
- Hematologic abnormalities, such as leukopenia, neutropenia, and agranulocytosis, necessitate regular complete blood count monitoring.
- Anticholinergic effects may worsen conditions like narrow-angle glaucoma or prostatic hypertrophy.
- Patients should be advised against operating machinery or driving due to potential sedation and blurred vision.
How it Works (Mechanism of Action)
Flupenthixol is a thioxanthene antipsychotic that exerts its therapeutic effects primarily through potent antagonism of dopamine D1 and D2 receptors in the central nervous system, particularly in the mesolimbic and mesocortical pathways. This blockade of dopamine receptors is believed to reduce the hyperactivity of dopamine, which is implicated in the pathophysiology of psychosis and schizophrenia. Beyond its strong dopaminergic antagonism, flupenthixol also exhibits weak antagonistic activity at alpha1-adrenergic receptors, serotonin 5-HT2 receptors, and has some mild antihistaminic (H1) and anticholinergic (muscarinic) properties. The combined effect of these receptor interactions contributes to its antipsychotic, anxiolytic, and antidepressant actions. The D2 receptor blockade is particularly crucial for its antipsychotic efficacy, while the additional receptor interactions may contribute to its side effect profile and potentially its ability to alleviate certain negative symptoms and mood disturbances at lower doses.